James Ward-Lilley appointed chief executive of Vectura

24 June 2015

UK developer of inhaled therapies Vectura (LSE: VEC) has appointed James Ward-Lilley as chief executive and executive director.

He joins the company from the beginning of October from AstraZeneca (LSE: AZN), where he is currently vice president of respiratory, inflammation and autoimmunity, global product and portfolio strategy. Prior to this, he led the company’s investor relations team.

Bruno Angelici, chairman of Vectura, said: “We are delighted that James is joining as CEO. His significant relevant experience in the respiratory market which he has gained within a major global pharmaceutical company will be a considerable asset for Vectura. James joins at an exciting and important time for Vectura and we are confident that the Company will continue to grow from strength to strength under his leadership.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK